Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 12 |
| List of Tables | 11 | 2 |
| List of Figures | 13 | 1 |
| Introduction | 14 | 1 |
| Global Markets Direct Report Coverage | 14 | 1 |
| Diabetic Retinopathy Overview | 15 | 1 |
| Therapeutics Development | 16 | 2 |
| Pipeline Products for Diabetic Retinopathy Overview | 16 | 1 |
| Pipeline Products for Diabetic Retinopathy Comparative Analysis | 17 | 1 |
| Diabetic Retinopathy Therapeutics under Development by Companies | 18 | 4 |
| Diabetic Retinopathy Therapeutics under Investigation by Universities/Institutes | 22 | 1 |
| Diabetic Retinopathy Pipeline Products Glance | 23 | 4 |
| Late Stage Products | 23 | 1 |
| Clinical Stage Products | 24 | 1 |
| Early Stage Products | 25 | 1 |
| Unknown Stage Products | 26 | 1 |
| Diabetic Retinopathy Products under Development by Companies | 27 | 4 |
| Diabetic Retinopathy Products under Investigation by Universities/Institutes | 31 | 1 |
| Diabetic Retinopathy Companies Involved in Therapeutics Development | 32 | 43 |
| Acucela Inc. | 32 | 1 |
| Aerie Pharmaceuticals, Inc. | 33 | 1 |
| Aerpio Therapeutics, Inc. | 34 | 1 |
| Amakem NV | 35 | 1 |
| Antisense Therapeutics Limited | 36 | 1 |
| Araim Pharmaceuticals, Inc. | 37 | 1 |
| BCN Peptides, S.A. | 38 | 1 |
| Biomar Microbial Technologies | 39 | 1 |
| Charlesson LLC. | 40 | 1 |
| Coherus BioSciences, Inc. | 41 | 1 |
| Crinetics Pharmaceuticals, Inc. | 42 | 1 |
| Diffusion Pharmaceuticals Inc | 43 | 1 |
| Dimerix Bioscience Pty Ltd | 44 | 1 |
| Dynamis Therapeutics, Inc. | 45 | 1 |
| EyeGene Inc | 46 | 1 |
| Foresee Pharmaceuticals, LLC | 47 | 1 |
| Formycon AG | 48 | 1 |
| Icon Bioscience, Inc. | 49 | 1 |
| Islet Sciences, Inc. | 50 | 1 |
| Kodiak Sciences Inc. | 51 | 1 |
| Kowa Company, Ltd. | 52 | 1 |
| LegoChem Biosciences, Inc | 53 | 1 |
| Lpath, Inc. | 54 | 1 |
| M's Science Corporation | 55 | 1 |
| Mabion SA | 56 | 1 |
| MingSight Pharmaceuticals | 57 | 1 |
| OcuCure Therapeutics, Inc. | 58 | 1 |
| Oculis ehf | 59 | 1 |
| Ohr Pharmaceutical Inc. | 60 | 1 |
| PanOptica, Inc. | 61 | 1 |
| Profarma | 62 | 1 |
| Promedior, Inc. | 63 | 1 |
| Regeneron Pharmaceuticals Inc | 64 | 1 |
| Retrotope, Inc | 65 | 1 |
| Ribomic Inc. | 66 | 1 |
| Stelic Institute &Co., Inc. | 67 | 1 |
| Stemedica Cell Technologies, Inc. | 68 | 1 |
| Strongbridge Biopharma plc | 69 | 1 |
| Sucampo Pharmaceuticals, Inc. | 70 | 1 |
| Targazyme, Inc. | 71 | 1 |
| ThromboGenics NV | 72 | 1 |
| TWi Pharmaceuticals, Inc. | 73 | 1 |
| VESSL Therapeutics Ltd | 74 | 1 |
| Diabetic Retinopathy Therapeutics Assessment | 75 | 14 |
| Assessment by Monotherapy Products | 75 | 1 |
| Assessment by Combination Products | 76 | 1 |
| Assessment by Target | 77 | 4 |
| Assessment by Mechanism of Action | 81 | 4 |
| Assessment by Route of Administration | 85 | 2 |
| Assessment by Molecule Type | 87 | 2 |
| Drug Profiles | 89 | 128 |
| (irbesartan + propagermanium) Drug Profile | 89 | 3 |
| A-717 Drug Profile | 92 | 1 |
| AC-301 Drug Profile | 93 | 1 |
| aflibercept Drug Profile | 94 | 11 |
| AKB-9778 Drug Profile | 105 | 4 |
| ALG-1001 Drug Profile | 109 | 3 |
| AMA-0428 Drug Profile | 112 | 1 |
| APTA-1004 Drug Profile | 113 | 1 |
| Aptamers for Diabetic Retinopathy Drug Profile | 114 | 1 |
| AR-13154 Drug Profile | 115 | 1 |
| atesidorsen sodium Drug Profile | 116 | 8 |
| Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications Drug Profile | 124 | 1 |
| BNN-27 Drug Profile | 125 | 1 |
| cibinetide Drug Profile | 126 | 3 |
| CLT-005 Drug Profile | 129 | 1 |
| CLT-020 Drug Profile | 130 | 1 |
| COR-005 Drug Profile | 131 | 3 |
| cyclosporine Drug Profile | 134 | 1 |
| Cyndacel-M Drug Profile | 135 | 1 |
| DMX-400 Drug Profile | 136 | 1 |
| Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy Drug Profile | 137 | 1 |
| DT-23552 Drug Profile | 138 | 1 |
| DYN-12 Drug Profile | 139 | 1 |
| E-1086 Drug Profile | 140 | 1 |
| EG-Mirotin Drug Profile | 141 | 1 |
| emixustat hydrochloride Drug Profile | 142 | 4 |
| FP-008 Drug Profile | 146 | 1 |
| GLY-230 Drug Profile | 147 | 1 |
| IB-09A0133 Drug Profile | 148 | 1 |
| IVMED-60 Drug Profile | 149 | 1 |
| JP-153 Drug Profile | 150 | 1 |
| KSI-301 Drug Profile | 151 | 1 |
| L-779976 Drug Profile | 152 | 1 |
| LCB-030110 Drug Profile | 153 | 1 |
| Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy Drug Profile | 154 | 1 |
| Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar Drug Profile | 155 | 1 |
| MS-553 Drug Profile | 156 | 1 |
| MultiGeneEye Drug Profile | 157 | 1 |
| Nextomabs Drug Profile | 158 | 1 |
| NM-108 Drug Profile | 159 | 1 |
| OC-10X Drug Profile | 160 | 1 |
| OC-410 Drug Profile | 161 | 1 |
| ocriplasmin Drug Profile | 162 | 6 |
| OCU-200 Drug Profile | 168 | 1 |
| OCX-063 Drug Profile | 169 | 1 |
| OLX-302 Drug Profile | 170 | 1 |
| PAN-90806 Drug Profile | 171 | 2 |
| PF-07 Drug Profile | 173 | 1 |
| PRM-167 Drug Profile | 174 | 1 |
| Protein for Oncology, Ophthalmology and Metabolic Disorders Drug Profile | 175 | 1 |
| ranibizumab biosimilar Drug Profile | 176 | 1 |
| ranibizumab biosimilar Drug Profile | 177 | 2 |
| ranibizumab biosimilar Drug Profile | 179 | 1 |
| RBM-008 Drug Profile | 180 | 1 |
| Recombinant Protein for Oncology and Diabetic Retinopathy Drug Profile | 181 | 1 |
| Recombinant Protein To Target Caspases for Diabetic Retinopathy, Macular Degeneration and Solid Tumor Drug Profile | 182 | 1 |
| RES-529 Drug Profile | 183 | 4 |
| ripasudil Drug Profile | 187 | 2 |
| RT-001 Drug Profile | 189 | 2 |
| RT-002 Drug Profile | 191 | 1 |
| RTU-1096 Drug Profile | 192 | 1 |
| somatostatin Drug Profile | 193 | 1 |
| squalamine lactate Drug Profile | 194 | 8 |
| Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile | 202 | 6 |
| Stem Cell Therapy for Diabetic Retinopathy Drug Profile | 208 | 1 |
| STNM-1510 Drug Profile | 209 | 1 |
| Synthetic Peptide to Agonize PEDF-R for Diabetic Retinopathy Drug Profile | 210 | 1 |
| THR-687 Drug Profile | 211 | 1 |
| TZ-101 Drug Profile | 212 | 3 |
| V-1932 Drug Profile | 215 | 1 |
| Wnt-001 Drug Profile | 216 | 1 |
| Diabetic Retinopathy Dormant Projects | 217 | 6 |
| Diabetic Retinopathy Discontinued Products | 223 | 1 |
| Diabetic Retinopathy Product Development Milestones | 224 | 12 |
| Featured News &Press Releases | 224 | 1 |
| Oct 14, 2016: PanOptica Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye Drop | 224 | 1 |
| Oct 03, 2016: Allegro Ophthalmics Announces Last Patient Enrolled In PACIFIC Phase 2b Clinical Trial Of Luminate For Non-Proliferative Diabetic Retinopathy | 225 | 1 |
| May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection | 225 | 1 |
| May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy | 226 | 1 |
| Feb 10, 2016: Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study | 226 | 1 |
| Jan 13, 2016: ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial | 227 | 1 |
| Nov 12, 2015: ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA for the Treatment of Non-Proliferative Diabetic Retinopathy | 228 | 1 |
| May 18, 2015: Allegro Ophthalmics Announces Issuance of U.S. Patent for First-in-Class Integrin Peptide Therapy Candidate Luminate | 229 | 1 |
| May 04, 2015: Allegro Ophthalmics Begins Phase 2 Clinical Study Of Luminate For Non-Proliferative Diabetic Retinopathy | 230 | 1 |
| Mar 25, 2015: EYLEA (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema | 230 | 1 |
| Feb 02, 2015: UTHSC Prof. Ryan Yates Receives $15,000 Grant Award from UT Research Foundation | 231 | 1 |
| Dec 01, 2014: EYLEA (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema | 232 | 1 |
| Apr 14, 2014: ThromboGenics provides update on JETREA | 233 | 1 |
| Feb 20, 2014: Positive Case Report on Ohr Pharmaceutical's Squalamine Presented at the 37th Annual Macula Society Meeting | 233 | 1 |
| May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting | 234 | 2 |
| Appendix | 236 | 2 |
| Methodology | 236 | 1 |
| Coverage | 236 | 1 |
| Secondary Research | 236 | 1 |
| Primary Research | 236 | 1 |
| Expert Panel Validation | 236 | 1 |
| Contact Us | 236 | 1 |
| Disclaimer | 237 | 1 |
